RenovoRx To Present Record $563K Q1 Revenue, Phase III Trial Update June 23
RNXT•RenovoRx CEO Shaun Bagai will present record Q1 2026 revenue of $563,000 and discuss accelerating RenovoCath adoption during the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23. The company expects Phase III TIGeR-PaC trial enrollment to complete by end-June and highlights FDA orphan drug designation for oxaliplatin.
1. CEO Presentation Details
Shaun Bagai, RenovoRx’s CEO, will present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23 at 12:30 PM ET, discussing key financial and clinical developments scheduled for a live webcast with replay available on the company’s website.
2. Q1 2026 Revenue and Commercialization
RenovoRx reported record first-quarter 2026 revenue of $563,000, following approximately $1.1 million in RenovoCath sales during its first full year of commercial efforts in 2025. Growth was driven by rising demand for the FDA-cleared RenovoCath device and an expanding base of repeat orders from high-volume cancer centers.
3. Phase III TIGeR-PaC Trial Progress
The company expects to complete enrollment in its Phase III TIGeR-PaC trial evaluating intra-arterial gemcitabine delivered via RenovoCath in locally advanced pancreatic cancer by the end of June 2026, with final data anticipated in mid-to-late 2027 under FDA investigational new drug regulations.
4. Orphan Drug Designation and Pipeline Expansion
RenovoRx secured FDA orphan drug designation for oxaliplatin in pancreatic cancer—its second for pancreatic indications and third overall—potentially granting seven years of market exclusivity upon approval. The company also supports investigator-initiated trials and a post-marketing registry to generate clinical data for its TAMP platform.
